RhumbLine Advisers’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.8M Buy
144,163
+4,318
+3% +$277K 0.01% 1061
2026
Q1
$7.88M Sell
139,845
-561
-0.4% -$36.5K 0.01% 1183
2025
Q4
$11.3M Sell
140,406
-16,466
-10% -$1.11M 0.01% 1006
2025
Q3
$7.65M Sell
156,872
-9,535
-6% -$590K 0.01% 1214
2025
Q2
$12.4M Buy
166,407
+5,284
+3% +$350K 0.01% 965
2025
Q1
$10.2M Buy
161,123
+1,861
+1% +$127K 0.01% 1007
2024
Q4
$12.4M Buy
159,262
+1,024
+0.6% +$82.2K 0.01% 955
2024
Q3
$12.7M Sell
158,238
-3,423
-2% -$277K 0.01% 954
2024
Q2
$13.4M Buy
161,661
+842
+0.5% +$74.1K 0.01% 889
2024
Q1
$13.7M Buy
160,819
+741
+0.5% +$58.2K 0.01% 899
2023
Q4
$13.7M Sell
160,078
-2,855
-2% -$247K 0.01% 885
2023
Q3
$14.6M Buy
162,933
+1,118
+0.7% +$99.8K 0.02% 796
2023
Q2
$13.8M Sell
161,815
-114
-0.1% -$9.64K 0.02% 848
2023
Q1
$13.4M Sell
161,929
-1,623
-1% -$131K 0.02% 820
2022
Q4
$12.9M Sell
163,552
-905
-0.6% -$72.7K 0.02% 812
2022
Q3
$12.2M Buy
164,457
+6,821
+4% +$490K 0.02% 789
2022
Q2
$10.3M Buy
157,636
+8,866
+6% +$525K 0.02% 885
2022
Q1
$9.4M Buy
148,770
+2,817
+2% +$153K 0.01% 983
2021
Q4
$7.74M Buy
145,953
+4,620
+3% +$281K 0.01% 1125
2021
Q3
$9.98M Buy
141,333
+1,085
+0.8% +$68.5K 0.01% 954
2021
Q2
$9.35M Buy
140,248
+3,192
+2% +$226K 0.01% 1047
2021
Q1
$15.2M Sell
137,056
-1,831
-1% -$227K 0.02% 738
2020
Q4
$16.5M Sell
138,887
-140
-0.1% -$15.1K 0.02% 637
2020
Q3
$12.1M Sell
139,027
-4,694
-3% -$410K 0.02% 675
2020
Q2
$12.9M Sell
143,721
-9,053
-6% -$914K 0.02% 655
2020
Q1
$15.2M Sell
152,774
-1,745
-1% -$189K 0.03% 478
2019
Q4
$17.8M Sell
154,519
-904
-0.6% -$109K 0.03% 531
2019
Q3
$19.6M Sell
155,423
-7,044
-4% -$894K 0.04% 452
2019
Q2
$19.6M Buy
162,467
+2,645
+2% +$260K 0.04% 454
2019
Q1
$14M Buy
159,822
+224
+0.1% +$20.4K 0.03% 584
2018
Q4
$16M Buy
159,598
+64,530
+68% +$6.78M 0.03% 507
2018
Q3
$10.9M Sell
95,068
-6,361
-6% -$659K 0.02% 644
2018
Q2
$9.1M Sell
101,429
-24,892
-20% -$2.1M 0.02% 726
2018
Q1
$9.24M Buy
126,321
+3,462
+3% +$238K 0.02% 700
2017
Q4
$7.14M Buy
122,859
+18,190
+17% +$958K 0.01% 849
2017
Q3
$4.7M Buy
104,669
+2,145
+2% +$89.1K 0.01% 1078
2017
Q2
$4.05M Sell
102,524
-3,747
-4% -$154K 0.01% 1127
2017
Q1
$4.31M Buy
106,271
+25,945
+32% +$1.01M 0.01% 1097
2016
Q4
$3.23M Sell
80,326
-3,396
-4% -$128K 0.01% 1169
2016
Q3
$3.03M Buy
83,722
+3,615
+5% +$124K 0.01% 1152
2016
Q2
$2.32M Sell
80,107
-1,462
-2% -$44.2K 0.01% 1244
2016
Q1
$2.85M Buy
81,569
+6,060
+8% +$196K 0.01% 1147
2015
Q4
$2.43M Buy
75,509
+935
+1% +$30.3K 0.01% 1223
2015
Q3
$2.41M Sell
74,574
-1,191
-2% -$44.8K 0.01% 1215
2015
Q2
$3.13M Sell
75,765
-10,835
-13% -$457K 0.01% 1123
2015
Q1
$3.89M Buy
86,600
+865
+1% +$36.2K 0.01% 979
2014
Q4
$3.21M Buy
85,735
+555
+0.7% +$20.3K 0.01% 1053
2014
Q3
$2.97M Sell
85,180
-2,930
-3% -$105K 0.01% 1058
2014
Q2
$3.11M Buy
88,110
+10,276
+13% +$343K 0.01% 1087
2014
Q1
$2.54M Sell
77,834
-2,900
-4% -$111K 0.01% 1200
2013
Q4
$3.4M Buy
80,734
+3,630
+5% +$149K 0.01% 1032
2013
Q3
$3.08M Sell
77,104
-2,034
-3% -$85.3K 0.01% 1079
2013
Q2
$3.27M Buy
+79,138
New +$3.2M 0.01% 1007

Other funds holding HAE

RhumbLine Advisers's HAE Position: Q2 2026 in Review

RhumbLine Advisers increased its Haemonetics (HAE) stake by 3.1% in Q2 2026, buying an estimated $277K and bringing the position to 144,163 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1061.

RhumbLine Advisers first reported a position in HAE in Q2 2013 and has held it in 53 quarters since. The position peaked at $19.6M in Q3 2019. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • RhumbLine Advisers held 144,163 shares of Haemonetics worth $10.8M as of Q2 2026.
  • RhumbLine Advisers bought 4,318 Haemonetics shares in Q2 2026, an estimated $277K.
  • Haemonetics made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1061 holding.
  • RhumbLine Advisers first reported a position in Haemonetics in Q2 2013 and has held it in 53 quarters since.
  • RhumbLine Advisers's Haemonetics position peaked at $19.6M in Q3 2019.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.